Nordson Posts 12% Revenue Jump in Q3

Nordson (NASDAQ:NDSN) reported robust Q3 FY2025 results, with GAAP revenue of $741.5 million and non-GAAP EPS of $2.73, both exceeding analyst estimates and representing 12.1% and 13% year-over-year increases, respectively. While overall organic growth was a modest 2%, primarily driven by acquisitions, the Advanced Technology Solutions segment delivered strong 15% organic growth, offsetting a 2% organic decline in Industrial Precision Solutions. Management updated full-year FY2025 guidance, now anticipating sales slightly below the original midpoint but profitability above it, alongside approving a new $500 million share repurchase program.

Analysis

Nordson (NDSN) delivered a robust third quarter for FY2025, with GAAP revenue of $741.5 million and non-GAAP EPS of $2.73, surpassing consensus estimates and growing 12.1% and 13% year-over-year, respectively. However, the headline growth masks a significant divergence in underlying performance. Overall organic growth was a modest 2%, indicating that recent acquisitions, notably Atrion, and currency effects were the primary drivers of the top-line beat. The Advanced Technology Solutions segment was the clear standout, posting an impressive 15% organic sales growth fueled by strong demand in electronics and semiconductor end-markets, which also drove its EBITDA margin up to 24%. Conversely, the core Industrial Precision Solutions segment registered a 2% organic sales decline, citing persistent weakness in polymer processing. The Medical and Fluid Solutions segment's 32% reported growth was almost entirely acquisition-driven. While the company demonstrated exceptional capital efficiency with free cash flow surging 58% to $226.4 million and a new $500 million share repurchase program was authorized, management issued a mixed outlook. Full-year FY2025 sales are now expected to be slightly below the original guidance midpoint, reflecting the softer demand in certain core areas, while profitability is guided to be slightly above the midpoint, signaling confidence in cost control and operational execution.

Key Decisions for Investors

• Investors should assess if the strong performance in the Advanced Technology Solutions segment can continue to offset the organic sales decline in the larger Industrial Precision Solutions segment.
• The revised guidance suggests a trade-off between top-line growth and profitability; therefore, monitor organic revenue trends closely, as any further deterioration could challenge the positive earnings outlook.
• Consider the strong free cash flow generation and the new $500 million share repurchase program as key factors providing downside support and a tangible return of capital.
• Factor in the pending divestiture of the medical contract manufacturing business and the ongoing integration of the Atrion acquisition, as these strategic moves will continue to influence segment-level performance and overall corporate results.